Hydrochloric Acid → (R)-7-(4-morpholinophenyl)-N-(piperidin-3-ylmethyl)pyrido[4,3-b]pyrazin-5-amine

HRID 57603

Reaktionsgleichung

Reaktionsgleichung von HRID 57603
[O:1]1[CH2:6][CH2:5][N:4]([C:7]2[CH:12]=[CH:11][C:10]([C:13]3[N:22]=[C:21]([NH:23][CH2:24][C@@H:25]4[CH2:30][CH2:29][CH2:28][N:27](C(OC(C)(C)C)=O)[CH2:26]4)[C:20]4[C:15](=[N:16][CH:17]=[CH:18][N:19]=4)[CH:14]=3)=[CH:9][CH:8]=2)[CH2:3][CH2:2]1.Cl>>[O:1]1[CH2:6][CH2:5][N:4]([C:7]2[CH:12]=[CH:11][C:10]([C:13]3[N:22]=[C:21]([NH:23][CH2:24][C@@H:25]4[CH2:30][CH2:29][CH2:28][NH:27][CH2:26]4)[C:20]4[C:15](=[N:16][CH:17]=[CH:18][N:19]=4)[CH:14]=3)=[CH:9][CH:8]=2)[CH2:3][CH2:2]1

Komponenten

3

Edukt 2

HCID 313Hydrochloric AcidHCID 71113712(S)-tert-butyl 3-((7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-ylamino)methyl)piperidine-1-carboxylate

Produkt 1

HCID 71113720(R)-7-(4-morpholinophenyl)-N-(piperidin-3-ylmethyl)pyrido[4,3-b]pyrazin-5-amine

Versuchsvorschrift

(S)-tert-butyl 3-((7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-ylamino)methyl)piperidine-1-carboxylate (0.11 mmol) was treated with HCl solution (in EtOAc, 4 N, 3 mL) at room temperature until the reaction was completed. The precipitates were collected by filtration and further purified by chromatography to afford the title compound. MS (m/z): 405 (M+H)+.

Aufarbeitung

  1. filtrationThe precipitates were collected by filtration
  2. customfurther purified by chromatography

Quellen und Nachweise

ORD-Eintrag
ord-a144049fdcd1463bb85e9c3227d953dd
Quelldatensatz
uspto-grants-2016_09
Patentnummer
US09434726B2

Verknüpfte Notizen

Wird geladen…